Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The need exists to further assess the antibacterial agent azithromycin at differing doses in an HIV-infected population.
Patients are randomized to receive azithromycin at 1 of 2 doses in a two-treatment, two-period, cross-over study. Dosing visits are separated by at least 14-day wash-out periods.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
HIV seropositivity.
CD4 count \<= 500 cells/mm3.
NO active AIDS opportunistic infection.
You may not be if
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Other active intercurrent illness.
Any condition possibly affecting drug absorption (e.g., ulcers, gastrectomy, HIV-associated enteropathies.
Signs or symptoms of severe illness that would preclude study participation.
Known allergies to macrolide antibiotics.
Patients with the following prior condition are excluded:
Clinically important change in baseline status within 4 weeks prior to study entry.
Prior Medication:
Excluded:
Investigational drugs including treatment IND drugs within 4 weeks prior to study entry.
Known drug or alcohol dependence.
Clareo Health | A Study of Azithromycin in HIV-Infected Patients
